- Email: [email protected]
- Telephone: +44 20 7242 8692
- Fax: +44 20 7405 4166
- Website: http://www.carpmaels.com
Partner at Carpmaels & Ransford LLP
James Warner leads the pharmaceuticals team at Carpmaels & Ransford. His practice focuses exclusively on medicinal chemistry inventions for pharmaceutical innovators and he is known for his imaginative approaches to legal and technical strategies on the most commercially important cases. His work is inevitably contentious in nature and he has considerable experience conducting multi-opponent EPO opposition proceedings. Mr Warner is one of only a handful of advocates to have first-hand experience of defending EPO oppositions with more than 10 opponents. He brings practical experience of the subtle interactions of patent, supplementary protection certificate and regulatory law to these commercial situations.
Mr Warner is particularly known for successfully prosecuting and defending new chemical entity, combination, formulation, second medical use and dosage regimen patents on marketed products. In this sphere, he has advised on most of Novartis’s blockbuster products and has led numerous successful EPO opposition defences to generic challenges – most notably the multi-party oppositions against Novartis’s Exforge (valsartan/amlodipine), Glivec (imatinib) and Jakavi (ruxolitinib) products. He is also the lead European outside patent counsel for Gilead’s HIV and HBV portfolios, successfully defending Gilead’s tenofovir alafenamide and cobicistat medicines – present in a variety of their blockbuster antiviral products – against multi-opponent oppositions. He represents Roche in EPO opposition and appeal proceedings and is a lead counsel for Janssen’s small molecule portfolio.
Mr Warner’s EPO opposition work frequently brings him into contact with parallel national litigation and he is particularly sought out to bring his EPO and technical experience to litigation strategies throughout Europe and the world.
Outside the small molecule space, Mr Warner has a long standing relationship with Ionis Pharmaceuticals, protecting its growing pipeline of antisense candidates.
Mr Warner has a first-class degree in chemistry from Oxford University, where he received various academic prizes including a scholarship, a Gibbs prize for final written examinations and, for his final-year dissertation work, the university research prize.